31 results about "Squamous cell carcinoma Antigen" patented technology

The invention discloses an integral detecting reacting board and protein chip agent box of Carcinoembryonic antigen,CEA, 15-3 CA15-3(Carbohydrate Antigen 15-3,CA15-3), CA 125 (Cancer antigen 125,CA125), Squamous cell carcinoma antigen,SCC, Human papillomavirus antibody,HPVAb, beta-human chorionic gonadotropin, beta-HCG and alpha-fetoprotein,AFP, wherein the reacting hole board contains base and reacting hole on the base; the reacting hole contains 2-384 sample holes, 2-200 standard sample holes; the fixing phase carrier is set on the bottom of each reacting hole, which is covered by seven antigen or antibody molecule arrays with anti-CEA, anti-CA15-3,anti-CA125,anti-SCC,HPV,anti- beta-HCG,anti-AFP.

In a first aspect thereof, the present invention provides a method for treatment and/or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator.

The invention discloses a model for predicating lung cancer risks for people suffering from pulmonary nodules among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The model comprises biomarkers, enzyme-labeled antibodies of the biomarkers, a carbonate buffer solution with the pH value being 9.6, a phosphate buffer solution with a pH value being 7.4, a serum protein diluent, a stop solution, a tetramethyl benzidine substrate solution, serum of normal people and positive control serum; the biomarkers are four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens and are combined with CT imageology parameters and other clinical indexes. The model can assist in screening of lung cancer.

The present invention relates to monoclonal antibodies capable of distinguishing squamous cell cancer antigens, SCCA, in either free or complex bound forms, preferably antigens SCCA1 and SCCA2, as well as hybridomas recognizing such antibodies, method for diagnosing SCC, as well as diagnostic kits for detecting SCCAs.

The invention discloses a method for enhancing the luminous intensity of a squamous-cell carcinoma antigen during electrochemical luminescence detection. The method mainly comprises a construction step of an electrochemical luminescence sensor, wherein the construction step comprises: preparing an SCCA solution with certain concentration, dripping the SCCA on a polymer molecular imprinting modified electrode for incubation, performing washing with water after the incubation is completed, then dripping a Fe-MIL-88-NH2 @ZnSe/Ab/BSA complex onto the electrode and incubating the same, performing washing with water after the incubation is completed, and drying to obtain the electrochemical luminescence sensor; and the prepared electrochemical luminescence sensor is placed in a PBS buffer solution containing a co-reactant to perform electrochemical luminescence detection, and then the luminous intensity of the SCCA during the electrochemical luminescence detection can be effectively. The electrochemical luminescence sensor constructed by the method disclosed by the invention has good selectivity and high sensitivity, and when the electrochemical luminescence sensor is applied to the electrochemical luminescence detection of the SCCA, the linear range of the method is effectively increased, and the detection sensitivity is improved.

The present invention relates to novel antibodies, antibody fragments and antibody conjugates which display a high degree of selectivity for squamous cell carcinoma antigens including carcinomas of the lung, esophagus and cervix. The present invention relates to both in vivo and in vitro clinical screening methods for diagnosis or prognosis of carcinomas by means of detecting the expression of squamous cell carcinoma antigens in biological samples of the subject using the novel antibodies of the invention. The invention further provides for kits for carrying out the above described screening methods. Additionally, antibody conjugates may be used to efficiently deliver various agents which have anti-tumor effects to the tumor cell. The antibodies of the invention may also be administered to a patient in non-conjugated form to target ADCC to the tumor cell.

The invention discloses a water-soluble Zn-Mg-Te quantum dot and a preparation method of a water-soluble Zn-Mg-Te quantum dot/titanium dioxide nanorod composite material, and belongs to the technicalfields of tumour marker detection, photoelectrochemistry and immune sensing. The water-soluble Zn-Mg-Te quantum dot/titanium dioxide nanorod composite material modifies an L-shaped glassy carbon electrode, the composite material is loaded with a squamous cell carcinoma antibody to form a photoelectric immunosensor, and on the basis of immunological reaction, the specificity of a squamous cell carcinoma antigen is detected by taking white light as a laser light source. The water-soluble Zn-Mg-Te quantum dots, the titanium dioxide nanorods and the white laser source are introduced into the photoelectric squamous cell carcinoma immunization sensing system, and the prepared photoelectric immunosensor has the advantages of being convenient, simple, economic, highly adaptive, simple and rapid inoperation, high in selectivity and sensitivity, and low in detecting limit.

The invention relates to a biomarker-spectrum-based lung cancer risk prediction kit for high-risk groups in rural China.The kit comprises reagents for measuring the serum protein spectrum expression quantity of the four biomarkers comprising gastrin release propeptide, the carcino-embryonic antigen, the cytokeratin 19 fragment and the squamous-cell carcinoma antigen.The kit is combined with other clinical indexes such as the age, smoking history, malignancy history and sex, and can be used for accurately predicting the lung cancer risk.

The invention provides a chemiluminescent immunoassay quantitative detection kit for squamous cell carcinoma antigens, which relates to the medical field of immunoassay. The kit of the invention is mainly composed of a squamous cell carcinoma antigenic temporary calibrator, a solid-phase vector which is coated by a squamous cell carcinoma antigenic antibody, a squamous cell carcinoma antigenic antibody which is marked by enzyme, a chemiluminescent substrate solution and a concentrated washing solution. The preparation method of the kit mainly comprises the following steps: the coating of the solid-phase vector, the preparation of the calibrator and enzyme markers and the preparation of the chemiluminescent substrate solution and the concentrated washing solution. With the kit and the preparation method thereof, the detection sensitivity, the linear range and the quantitative accuracy can be improved. The invention has convenient use, safety and stability.

The invention belongs to the technical field of biomedical detection and particularly relates to a marker for cervical cancer detection and a detection kit. The marker comprises a squamous cell carcinoma antigen, a carcino-embryonic antigen, a carbohydrate antigen 125, a carbohydrate antigen 199 and a human epididymal protein 4, acridinium ester is adopted for direct chemiluminescence, an antibody (antigen) is directly labeled with acridinium ester, after immunoreaction with a corresponding antigen (antibody) of a sample to be detected, a coated antibody-antigen to be detected-acridinium ester labeled antibody compound is formed, excitation liquid is added, and decomposition and luminescence can be achieved without a catalyst. A combination of multiple tumor markers is established, detection specificity and sensitivity of cervical cancer are improved through combined detection of multiple indexes, detection sensitivity and accuracy are high when serum detection is carried out on a cervical cancer patient, combined detection can have a high detection rate on tumors, and early screening, treatment effect and postoperative recurrence of cervical cancer patients can be dynamically monitored.

The invention discloses a cell carcinoma antigen hybridoma cell strain and an application method of a monoclonal antibody of the cell carcinoma antigen hybridoma cell strain. The antibody for detecting SCC is an antigen polypeptide sequence specifically designed according to the sequence characteristics of SCCA1 and SCCA2, and is used as an antigen to immunize BALB/c mice, a hybridoma cell strain4H8 for generating the antibody is obtained by using a cell fusion technology, and the antibody secreted by hybridoma cells is IgG1 positive; the invention provides the hybridoma cell strain secretingthe monoclonal antibody, the preservation number of the hybridoma cell strain is CCTCC NO: C2019315, and the hybridoma cell strain can stably secrete a high-titer monoclonal antibody for resisting squamous cell carcinoma antigen. An immune reagent developed by using the squamous cell carcinoma antigen-antibody provided by the invention can accurately determine squamous cell carcinoma antigens ina serum sample, can simultaneously detect SCCA1 and SCCA2, has high sensitivity and accuracy, has high correlation with detection results of imported reagents sold on the market, and can replace imported antibodies, so that the production cost is reduced.